Trial Profile

RAte Control Efficacy in Permanent Atrial Fibrillation, a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antiarrhythmics; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Digoxin; Diltiazem; Sotalol; Verapamil
Indications Atrial fibrillation
Focus Therapeutic Use
Acronyms RACE-II

Most Recent Events

15 Mar 2010 Results have been published online in The New England Journal of Medicine.
15 Mar 2010 The composite primary endpoint has been met.
15 Mar 2010 Results were presented as a late breaking abstract at the 59th Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com